Company: INTS
Filing Date: 2025-06-02
Form Type: DEF 14A
Source: 0001567264-25-000050
Chunk: 14

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-06-02
Form: DEF 14A
Chunk 14
---
 of common stock issuable upon the exercise of warrants held by Mr. Duchossois exercisable within 60 days of May 31, 2025. Mr. Duchossois may be deemed to beneficially own such shares. The principal business address of Craig J. Duchossois is 444 W. Lake St, Suite 2000, Chicago, Illinois 60606. This information is based solely on information provided by the beneficial owner to the Company on May 16, 2025.

<div align='center'>9</div>

#### MANAGEMENT AND CORPORATE GOVERNANCE

#### Our Board of Directors
Our business is managed by or under the direction of our board of directors. Our board of directors is divided into three classes for purposes of election. One class is elected at each annual meeting of stockholders to serve for a three-year term. Our board of directors currently consists of five members, classified into three classes as follows: (1) Dr. Mark A. Goldberg constitutes a class with a term ending at the 2025 annual meeting; (2) Dr. Emer Leahy and Lewis H. Bender constitute a class with a term ending at the 2026 annual meeting; and (3) Daniel Donovan and Thomas I. H. Dubin constitute a class with a term ending at the 2027 annual meeting.

On May 15, 2025, our board of directors accepted the recommendation of the nominating and corporate governance committee (the “nominating committee”) and voted to nominate Dr. Mark A. Goldberg for election at the annual meeting for a term of three years to serve until the 2028 annual meeting of stockholders, and until his respective successor has been elected and qualified.

Set forth below are the names of the persons nominated for election as directors and those directors whose terms do not expire this year, their ages, their offices in the Company, if any, their principal occupations or employment for at least the past five years, the length of their tenure as directors and the names of other public companies in which such persons hold or have held directorships during the past five years as of June 2, 2025. Additionally, information about the specific experience, qualifications, attributes or skills that led to our board of directors’ conclusion at the time of filing of this proxy statement that each person listed below should serve as a director is set forth below:

| Name               |     | Age |     | Position with the Company                                                 |
| Lewis H. Bender    |